Bench-to-bedside review: Ventilation-induced renal injury through systemic mediator release - just theory or a causal relationship?

Critical Care

Volumn 15, Issue 4, 2011, Pages

  Kuiper, Jan W ^a   Vaschetto, Rosanna ^a,b   Corte, Francesco D ^b   Plötz, Frans B ^c   Groeneveld, AB Johan ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CASPASE 8; CYTOCHROME C; GLUCOSE; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; SODIUM; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UREA; VASCULOTROPIN; AUTACOID;

ACUTE KIDNEY FAILURE; APOPTOSIS; ARTIFICIAL VENTILATION; BLOOD CLOTTING; CYTOKINE RELEASE; CYTOSOL; DISEASE ASSOCIATION; ENZYME ACTIVATION; FIBRINOLYSIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; LIPID METABOLISM; MEDIATOR RELEASE; MESANGIUM CELL; MITOCHONDRION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SEPTIC SHOCK; BLOOD; INTENSIVE CARE UNIT; THEORETICAL MODEL;

ACUTE KIDNEY INJURY; HUMANS; INFLAMMATION MEDIATORS; INTENSIVE CARE UNITS; MODELS, THEORETICAL; RESPIRATION, ARTIFICIAL;

EID: 84865141300     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10282     Document Type: Review

References (221)

1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, . Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818. 10.1001/jama.294.7.813, 16106006, Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators.
2. Mehta RL, Pascual MT, Gruta CG, Zhuang S, Chertow GM. Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol 2002, 13:1350-1357. 10.1097/01.ASN.0000014692.19351.52, 11961023.
3. Kuiper JW, Groeneveld AB, Slutsky AS, Plotz FB. Mechanical ventilation and acute renal failure. Crit Care Med 2005, 33:1408-1415. 10.1097/01.CCM.0000165808.30416.EF, 15942363.
4. Slutsky AS, Tremblay LN. Multiple system organ failure. Is mechanical ventilation a contributing factor?. Am J Respir Crit Care Med 1998, 157:1721-1725.
5. The Acute Respiratory Distress Syndrome Network Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000, 342:1301-1308. The Acute Respiratory Distress Syndrome Network.
6. Tremblay LN, Slutsky AS. Ventilator-induced injury: from barotrauma to biotrauma. Proc Assoc Am Physicians 1998, 110:482-488.
7. Plotz FB, Slutsky AS, van Vught AJ, Heijnen CJ. Ventilator-induced lung injury and multiple system organ failure: a critical review of facts and hypotheses. Intensive Care Med 2004, 30:1865-1872. 10.1007/s00134-004-2363-9, 15221129.
8. Uhlig S. Ventilation-induced lung injury and mechanotransduction: stretching it too far?. Am J Physiol Lung Cell Mol Physiol 2002, 282:L892-L896.
9. Ranieri M, Giunta F, Suter PM, Slutsky AS. Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. JAMA 2000, 284:43-44. 10.1001/jama.284.1.43, 10872010.
10. Imai Y, Parodo J, Kajikawa O, de Perrot M, Fischer S, Edwards V, Cutz E, Liu M, Keshavjee S, Martin TR, Marshall JC, Ranieri VM, Slutsky AS. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA 2003, 289:2104-2112. 10.1001/jama.289.16.2104, 12709468.
11. Crimi E, Zhang H, Han RN, Del Sorbo L, Ranieri VM, Slutsky AS. Ischemia and reperfusion increases susceptibility to ventilator-induced lung injury in rats. Am J Respir Crit Care Med 2006, 174:178-186. 10.1164/rccm.200507-1178OC, 16645175.
12. Dhanireddy S, Altemeier WA, Matute-Bello G, O'Mahony DS, Glenny RW, Martin TR, Liles WC. Mechanical ventilation induces inflammation, lung injury, and extra-pulmonary organ dysfunction in experimental pneumonia. Lab Invest 2006, 86:790-799. 10.1038/labinvest.3700440, 16855596.
13. O'Mahony DS, Liles WC, Altemeier WA, Dhanireddy S, Frevert CW, Liggitt D, Martin TR, Matute-Bello G. Mechanical ventilation interacts with endotoxemia to induce extrapulmonary organ dysfunction. Crit Care 2006, 10:R136-R144. 10.1186/cc5050, 1751060, 16995930.
14. Vaschetto R, Kuiper JW, Chiang SR, Haitsma JJ, Juco JW, Uhlig S, Plotz FB, Corte FD, Zhang H, Slutsky AS. Inhibition of poly(adenosine diphosphateribose) polymerase attenuates ventilator-induced lung injury. Anesthesiology 2008, 108:261-268. 10.1097/01.anes.0000299434.86640.15, 18212571.
15. Kuiper JW, Versteilen AM, Niessen HW, Vaschetto RR, Sipkema P, Heijnen CJ, Groeneveld AB, Plotz FB. Production of endothelin-1 and reduced blood flow in the rat kidney during lung-injurious mechanical ventilation. Anesth Analg 2008, 107:1276-1283. 10.1213/ane.0b013e31818067a2, 18806040.
16. Haitsma JJ, Schultz MJ, Hofstra JJ, Kuiper JW, Juco J, Vaschetto R, Levi M, Zhang H, Slutsky AS. Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia. Eur Respir J 2008, 32:1599-1606. 10.1183/09031936.00045908, 18768578.
17. Chen CM, Chou HC, Wang LF, Lang YD. Captopril decreases plasminogen activator inhibitor-1 in rats with ventilator-induced lung injury. Crit Care Med 2008, 36:1880-1885. 10.1097/CCM.0b013e31817c911d, 18520644.
18. Choi WI, Quinn DA, Park KM, Moufarrej RK, Jafari B, Syrkina O, Bonventre JV, Hales CA. Systemic microvascular leak in an in vivo rat model of ventilator-induced lung injury. Am J Respir Crit Care Med 2003, 167:1627-1632. 10.1164/rccm.200210-1216OC, 12663326.
19. Calfee CS, Eisner MD, Parsons PE, Thompson BT, Conner ER, Matthay MA, Ware LB. Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. Intensive Care Med 2008, 35:248-257. 2790376, 18670758.
20. Eisner MD, Parsons P, Matthay MA, Ware L, Greene K. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003, 58:983-988. 10.1136/thorax.58.11.983, 1746524, 14586055.
21. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005, 33:1-6.
22. Parsons PE, Matthay MA, Ware LB, Eisner MD. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005, 288:L426-L431. 10.1152/ajplung.00302.2004, 15516488.
23. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno F, Slutsky AS. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999, 282:54-61. 10.1001/jama.282.1.54, 10404912.
24. Stuber F, Wrigge H, Schroeder S, Wetegrove S, Zinserling J, Hoeft A, Putensen C. Kinetic and reversibility of mechanical ventilation-associated pulmonary and systemic inflammatory response in patients with acute lung injury. Intensive Care Med 2002, 28:834-841. 10.1007/s00134-002-1321-7, 12122519.
25. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007, 35:1821-1828. 10.1097/01.CCM.0000221922.08878.49, 2764536, 17667242.
26. Kobr J, Fremuth J, Pizingerova K, Fikrlova S, Jehlicka P, Honomichl P, Sasek L, Racek J, Topolcan O. Total body response to mechanical ventilation of healthy lungs: an experimental study in piglets. Physiol Res 2010, 59:545-552.
27. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986, 234:470-474. 10.1126/science.3764421, 3764421.
28. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 1989, 134:419-430. 1879578, 2916653.
29. Baud L, Oudinet JP, Bens M, Noe L, Peraldi MN, Rondeau E, Etienne J, Ardaillou R. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 1989, 35:1111-1118. 10.1038/ki.1989.98, 2549293.
30. Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E, Egido J. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. J Immunol 1994, 153:5247-5255.
31. Nakamura A, Johns EJ, Imaizumi A, Niimi R, Yanagawa Y, Kohsaka T. Role of angiotensin II-induced cAMP in mesangial TNF-alpha production. Cytokine 2002, 19:47-51. 10.1006/cyto.2002.1040, 12200113.
32. Noiri E, Kuwata S, Nosaka K, Tokunaga K, Juji T, Shibata Y, Kurokawa K. Tumor necrosis factor-alpha mRNA expression in lipopolysaccharide-stimulated rat kidney. Chronological analysis of localization. Am J Pathol 1994, 144:1159-1166. 1887456, 8203457.
33. Neale TJ, Ruger BM, Macaulay H, Dunbar PR, Hasan Q, Bourke A, Murray-McIntosh RP, Kitching AR. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 1995, 146:1444-1454. 1870891, 7778683.
34. Gomez-Chiarri M, Ortiz A, Lerma JL, Lopez-Armada MJ, Mampaso F, Gonzalez E, Egido J. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab Invest 1994, 70:449-459.
35. Wuthrich RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE. MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. Kidney Int 1990, 37:783-792. 10.1038/ki.1990.46, 2407890.
36. Jevnikar AM, Brennan DC, Singer GG, Heng JE, Maslinski W, Wuthrich RP, Glimcher LH, Kelley VE. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha. Kidney Int 1991, 40:203-211. 10.1038/ki.1991.201, 1942768.
37. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002, 110:835-842. 151130, 12235115.
38. Wu SH, Lu C, Dong L, Zhou GP, He ZG, Chen ZQ. Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int 2005, 68:35-46. 10.1111/j.1523-1755.2005.00379.x, 15954894.
39. Pfeilschifter J, Pignat W, Leighton J, Marki F, Vosbeck K, Alkan S. Transforming growth factor beta 2 differentially modulates interleukin-1 beta- and tumour-necrosis-factor-alpha-stimulated phospholipase A2 and prostaglandin E2 synthesis in rat renal mesangial cells. Biochem J 1990, 270:269-271. 1131710, 2396988.
40. Hartner A, Sterzel RB, Reindl N, Hocke GM, Fey GH, Goppelt-Struebe M. Cytokine-induced expression of leukemia inhibitory factor in renal mesangial cells. Kidney Int 1994, 45:1562-1571. 10.1038/ki.1994.206, 7933804.
41. Bijuklic K, Sturn DH, Jennings P, Kountchev J, Pfaller W, Wiedermann CJ, Patsch JR, Joannidis M. Mechanisms of neutrophil transmigration across renal proximal tubular HK-2 cells. Cell Physiol Biochem 2006, 17:233-244. 10.1159/000094128, 16790999.
42. Bijuklic K, Jennings P, Kountchev J, Hasslacher J, Aydin S, Sturn D, Pfaller W, Patsch JR, Joannidis M. Migration of leukocytes across an endothelium-epithelium bilayer as a model of renal interstitial inflammation. Am J Physiol Cell Physiol 2007, 293:C486-C492. 10.1152/ajpcell.00419.2006, 17428840.
43. Ikeda M, Minota S, Kano S. Regulation of MHC class I expression by inflammatory cytokines in rat mesangial cells. Nephron 1997, 76:90-95. 10.1159/000190146, 9171306.
44. Pai R, Ha H, Kirschenbaum MA, Kamanna VS. Role of tumor necrosis factor-alpha on mesangial cell MCP-1 expression and monocyte migration: mechanisms mediated by signal transduction. J Am Soc Nephrol 1996, 7:914-923.
45. Thorburn E, Kolesar L, Brabcova E, Petrickova K, Petricek M, Jaresova M, Slavcev A, Striz I. CXC and CC chemokines induced in human renal epithelial cells by inflammatory cytokines. APMIS 2009, 117:477-487. 10.1111/j.1600-0463.2009.02446.x, 19594487.
46. Kamanna VS, Pai R, Bassa B, Kirschenbaum MA. Activation of mesangial cells with TNF-alpha stimulates M-CSF gene expression and monocyte proliferation: evidence for involvement of protein kinase C and protein tyrosine kinase. Biochim Biophys Acta 1996, 1313:161-172. 10.1016/0167-4889(96)00064-X, 8781564.
47. Brennan DC, Jevnikar AM, Takei F, Reubin-Kelley VE. Mesangial cell accessory functions: mediation by intercellular adhesion molecule-1. Kidney Int 1990, 38:1039-1046. 10.1038/ki.1990.310, 1981601.
48. Neumann B, Machleidt T, Lifka A, Pfeffer K, Vestweber D, Mak TW, Holzmann B, Kronke M. Crucial role of 55-kilodalton TNF receptor in TNF-induced adhesion molecule expression and leukocyte organ infiltration. J Immunol 1996, 156:1587-1593.
49. Brady HR, Spertini O, Jimenez W, Brenner BM, Marsden PA, Tedder TF. Neutrophils, monocytes, and lymphocytes bind to cytokine-activated kidney glomerular endothelial cells through L-selectin (LAM-1) in vitro. J Immunol 1992, 149:2437-2444.
50. Wu X, Guo R, Chen P, Wang Q, Cunningham PN. TNF induces caspase-dependent inflammation in renal endothelial cells through a Rho- and myosin light chain kinase-dependent mechanism. Am J Physiol Renal Physiol 2009, 297:F316-F326. 10.1152/ajprenal.00089.2009, 19420112.
51. Misseri R, Meldrum DR, Dinarello CA, Dagher P, Hile KL, Rink RC, Meldrum KK. TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 2005, 288:F406-F411.
52. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002, 168:5817-5823.
53. Wan B, Hao L, Qiu Y, Sun Z, Cao Q, Zhang Y, Zhu T, Wang H, Zhang Y. Blocking tumor necrosis factor-alpha inhibits folic acid-induced acute renal failure. Exp Mol Pathol 2006, 81:211-216. 10.1016/j.yexmp.2006.02.005, 16595132.
54. Messmer UK, Briner VA, Pfeilschifter J. Tumor necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells. Kidney Int 1999, 55:2322-2337. 10.1046/j.1523-1755.1999.00473.x, 10354280.
55. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996, 274:1855-1859. 10.1126/science.274.5294.1855, 8943189.
56. Huwiler A, Dorsch S, Briner VA, van den BH, Pfeilschifter J. Nitric oxide stimulates chronic ceramide formation in glomerular endothelial cells. Biochem Biophys Res Commun 1999, 258:60-65. 10.1006/bbrc.1999.0582, 10222235.
57. Huwiler A, Pfeilschifter J, van den BH. Nitric oxide donors induce stress signaling via ceramide formation in rat renal mesangial cells. J Biol Chem 1999, 274:7190-7195. 10.1074/jbc.274.11.7190, 10066779.
58. Hruby ZW, Cybulsky AV, Lowry RP. Effects of tumor necrosis factor on glomerular mesangial and epithelial cells in culture. Nephron 1990, 56:410-413. 10.1159/000186185, 2080000.
59. Radeke HH, Meier B, Topley N, Floge J, Habermehl GG, Resch K. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int 1990, 37:767-775. 10.1038/ki.1990.44, 2407888.
60. Baud L, Perez J, Friedlander G, Ardaillou R. Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. FEBS Lett 1988, 239:50-54. 10.1016/0014-5793(88)80543-X, 2846348.
61. Topley N, Floege J, Wessel K, Hass R, Radeke HH, Kaever V, Resch K. Prostaglandin E2 production is synergistically increased in cultured human glomerular mesangial cells by combinations of IL-1 and tumor necrosis factor-alpha 1. J Immunol 1989, 143:1989-1995.
62. Kohan DE. Production of endothelin-1 by rat mesangial cells: regulation by tumor necrosis factor. J Lab Clin Med 1992, 119:477-484.
63. Savic V, Stefanovic V, Ardaillou N, Ardaillou R. Induction of ecto-5'-nucleotidase of rat cultured mesangial cells by interleukin-1 beta and tumour necrosis factor-alpha. Immunology 1990, 70:321-326. 1384160, 2165999.
64. Marsden PA, Ballermann BJ. Tumor necrosis factor alpha activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism. J Exp Med 1990, 172:1843-1852. 10.1084/jem.172.6.1843, 2188772, 1979590.
65. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol 1992, 262:C854-C861.
66. Camussi G, Turello E, Tetta C, Bussolino F, Baglioni C. Tumor necrosis factor induces contraction of mesangial cells and alters their cytoskeletons. Kidney Int 1990, 38:795-802. 10.1038/ki.1990.273, 2266661.
67. Floege J, Topley N, Wessel K, Kaever V, Radeke H, Hoppe J, Kishimoto T, Resch K. Monokines and platelet-derived growth factor modulate prostanoid production in growth arrested, human mesangial cells. Kidney Int 1990, 37:859-869. 10.1038/ki.1990.59, 2107353.
68. Pfeilschifter J, Pignat W, Vosbeck K, Marki F. Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. Biochem Biophys Res Commun 1989, 159:385-394. 10.1016/0006-291X(89)90003-X, 2784674.
69. Pfeilschifter J, Muhl H. Interleukin 1 and tumor necrosis factor potentiate angiotensin II- and calcium ionophore-stimulated prostaglandin E2 synthesis in rat renal mesangial cells. Biochem Biophys Res Commun 1990, 169:585-595. 10.1016/0006-291X(90)90371-S, 2113380.
70. Piepot HA, Groeneveld AB, van Lambalgen AA, Sipkema P. Tumor necrosis factor-alpha impairs endothelium-dependent relaxation of rat renal arteries, independent of tyrosine kinase. Shock 2002, 17:394-398. 10.1097/00024382-200205000-00009, 12022760.
71. Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro PE, Esson M, Edelstein CL, Dinarello CA, Schrier RW. Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 2001, 59:2243-2249.
72. Schmidt C, Hocherl K, Kurt B, Moritz S, Kurtz A, Bucher M. Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock. Cytokine 2010, 49:30-38. 10.1016/j.cyto.2009.10.006, 19914088.
73. Glynne PA, Picot J, Evans TJ. Coexpressed nitric oxide synthase and apical beta(1) integrins influence tubule cell adhesion after cytokine-induced injury. J Am Soc Nephrol 2001, 12:2370-2383.
74. Martin M, Schwinzer R, Schellekens H, Resch K. Glomerular mesangial cells in local inflammation. Induction of the expression of MHC class II antigens by IFN-gamma. J Immunol 1989, 142:1887-1894.
75. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991, 88:1346-1353. 10.1172/JCI115440, 295605, 1918385.
76. Wiggins RC, Njoku N, Sedor JR. Tissue factor production by cultured rat mesangial cells. Stimulation by TNF alpha and lipopolysaccharide. Kidney Int 1990, 37:1281-1285. 10.1038/ki.1990.112, 2345426.
77. Schmidt C, Hocherl K, Schweda F, Bucher M. Proinflammatory cytokines cause down-regulation of renal chloride entry pathways during sepsis. Crit Care Med 2007, 35:2110-2119. 10.1097/01.ccm.0000281447.22966.8b, 17855824.
78. Schmidt C, Hocherl K, Bucher M. Regulation of renal glucose transporters during severe inflammation. Am J Physiol Renal Physiol 2007, 292:F804-F811.
79. Schmidt C, Hocherl K, Bucher M. Cytokine-mediated regulation of urea transporters during experimental endotoxemia. Am J Physiol Renal Physiol 2007, 292:F1479-F1489. 10.1152/ajprenal.00460.2006, 17229673.
80. Schmidt C, Hocherl K, Schweda F, Kurtz A, Bucher M. Regulation of renal sodium transporters during severe inflammation. J Am Soc Nephrol 2007, 18:1072-1083. 10.1681/ASN.2006050454, 17314327.
81. Wang Y, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Downregulation of liver X receptor-alpha in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines. J Lipid Res 2005, 46:2377-2387. 10.1194/jlr.M500134-JLR200, 16106051.
82. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196. 10.1194/jlr.R300019-JLR200, 15102878.
83. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2008, 1143:1-20. 10.1196/annals.1443.020, 19076341.
84. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006, 442:39-44. 10.1038/nature04946, 16823444.
85. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
86. Tesch GH, Yang N, Yu H, Lan HY, Foti R, Chadban SJ, Atkins RC, Nikolic-Paterson DJ. Intrinsic renal cells are the major source of interleukin-1 beta synthesis in normal and diseased rat kidney. Nephrol Dial Transplant 1997, 12:1109-1115. 10.1093/ndt/12.6.1109, 9198037.
87. Luo DD, Fielding C, Phillips A, Fraser D. Interleukin-1 beta regulates proximal tubular cell transforming growth factor beta-1 signalling. Nephrol Dial Transplant 2009, 24:2655-2665. 10.1093/ndt/gfp208, 19420104.
88. Pfeilschifter J, Huwiler A. Identification of ceramide targets in interleukin-1 and tumor necrosis factor-alpha signaling in mesangial cells. Kidney Int Suppl 1998, 67:S34-S39.
89. Abbott F, Ryan JJ, Ceska M, Matsushima K, Sarraf CE, Rees AJ. Interleukin-1 beta stimulates human mesangial cells to synthesize and release interleukins-6 and -8. Kidney Int 1991, 40:597-605. 10.1038/ki.1991.250, 1745007.
90. Rovin BH, Yoshiumura T, Tan L. Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J Immunol 1992, 148:2148-2153.
91. Lee MJ, Yang CW, Jin DC, Chang YS, Bang BK, Kim YS. Bone morphogenetic protein-7 inhibits constitutive and interleukin-1 beta-induced monocyte chemoattractant protein-1 expression in human mesangial cells: role for JNK/AP-1 pathway. J Immunol 2003, 170:2557-2563.
92. Zoja C, Wang JM, Bettoni S, Sironi M, Renzi D, Chiaffarino F, Abboud HE, Van Damme J, Mantovani A, Remuzzi G, et al. Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol 1991, 138:991-1003. 1886116, 2012180.
93. Ikeda M, Ikeda U, Shimada K, Minota S, Kano S. Regulation of ICAM-1 expression by inflammatory cytokines in rat mesangial cells. Cytokine 1996, 8:109-114. 10.1006/cyto.1996.0015, 8777267.
94. Guan Z, Buckman SY, Springer LD, Morrison AR. Both p38alpha(MAPK) and JNK/SAPK pathways are important for induction of nitric-oxide synthase by interleukin-1beta in rat glomerular mesangial cells. J Biol Chem 1999, 274:36200-36206. 10.1074/jbc.274.51.36200, 10593906.
95. Kihara M, Yabana M, Toya Y, Kobayashi S, Fujita T, Iwamoto T, Ishigami T, Umemura S. Angiotensin II inhibits interleukin-1 beta-induced nitric oxide production in cultured rat mesangial cells. Kidney Int 1999, 55:1277-1283. 10.1046/j.1523-1755.1999.00377.x, 10200991.
96. Tateyama F, Yamabe H, Osawa H, Kaizuka M, Shirato K, Okumura K. Interleukin-1beta is an autocrine growth factor of rat glomerular epithelial cells in culture. Nephrol Dial Transplant 2001, 16:1149-1155. 10.1093/ndt/16.6.1149, 11390713.
97. Lang D, Terstesse M, Dohle F, Bangen P, Banas B, Pauels HG, Heidenreich S. Protein kinase C (PKC) dependent induction of tissue factor (TF) by mesangial cells in response to inflammatory mediators and release during apoptosis. Br J Pharmacol 2002, 137:1116-1124. 10.1038/sj.bjp.0704967, 1573586, 12429585.
98. Eberhardt W, Beck KF, Pfeilschifter J. Cytokine-induced expression of tPA is differentially modulated by NO and ROS in rat mesangial cells. Kidney Int 2002, 61:20-30. 10.1046/j.1523-1755.2002.00087.x, 11786081.
99. Gadient RA, Patterson PH. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells 1999, 17:127-137. 10.1002/stem.170127, 10342555.
100. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001, 15:43-58. 10.1096/fj.99-1003rev, 11149892.
101. Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May L, Stern D. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem 1995, 270:11463-11471. 10.1074/jbc.270.19.11463, 7744784.
102. Sekiyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 1994, 98:71-77. 1534161, 7923888.
103. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997, 79:1128-1131. 10.1016/S0002-9149(96)00063-X, 9114781.
104. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA, . PICARD Study Group Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004, 65:1357-1365. 10.1111/j.1523-1755.2004.00512.x, 15086475, PICARD Study Group.
105. Patel NS, Chatterjee PK, Di Paola R, Mazzon E, Britti D, De Sarro A, Cuzzocrea S, Thiemermann C. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther 2005, 312:1170-1178.
106. Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, Axelrod JH. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 2008, 19:1106-1115. 10.1681/ASN.2007070744, 2396933, 18337485.
107. Kielar ML, John R, Bennett M, Richardson JA, Shelton JM, Chen L, Jeyarajah DR, Zhou XJ, Zhou H, Chiquett B, Nagami GT, Lu CY. Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol 2005, 16:3315-3325. 10.1681/ASN.2003090757, 16192425.
108. Mitazaki S, Kato N, Suto M, Hiraiwa K, Abe S. Interleukin-6 deficiency accelerates cisplatin-induced acute renal failure but not systemic injury. Toxicology 2009, 265:115-121. 10.1016/j.tox.2009.10.005, 19833167.
109. Liu Y, Tolbert EM, Sun AM, Dworkin LD. Primary structure of rat HGF receptor and induced expression in glomerular mesangial cells. Am J Physiol 1996, 271:F679-F688.
110. Liu Y, Tolbert EM, Lin L, Thursby MA, Sun AM, Nakamura T, Dworkin LD. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int 1999, 55:442-453. 10.1046/j.1523-1755.1999.00267.x, 9987069.
111. Homsi E, Ribeiro-Alves MA, Lopes de Faria JB, Dias EP. Interleukin-6 stimulates tubular regeneration in rats with glycerol-induced acute renal failure. Nephron 2002, 92:192-199. 10.1159/000064478, 12187102.
112. Ruef C, Budde K, Lacy J, Northemann W, Baumann M, Sterzel RB, Coleman DL. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int 1990, 38:249-257. 10.1038/ki.1990.193, 2402117.
113. Horii Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, Fujii Y, Dohi K, Ishikawa H, Ohmoto Y, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 1989, 143:3949-3955.
114. Ikeda M, Ikeda U, Ohara T, Kusano E, Kano S. Recombinant interleukin-6 inhibits the growth of rat mesangial cells in culture. Am J Pathol 1992, 141:327-334. 1886620, 1497090.
115. Sharyo S, Kumagai K, Yokota-Ikeda N, Ito K, Ikeda M. Amelioration of renal ischemia-reperfusion injury by inhibition of IL-6 production in the poloxamer 407-induced mouse model of hyperlipidemia. J Pharmacol Sci 2009, 110:47-54. 10.1254/jphs.08283FP, 19403996.
116. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008, 226:205-218. 10.1111/j.1600-065X.2008.00706.x, 2724982, 19161426.
117. Wattanathum A, Manocha S, Groshaus H, Russell JA, Walley KR. Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis. Chest 2005, 128:1690-1698. 10.1378/chest.128.3.1690, 16162776.
118. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001, 60:2118-2128. 10.1046/j.1523-1755.2001.00043.x, 11737586.
119. Fouqueray B, Boutard V, Philippe C, Kornreich A, Marchant A, Perez J, Goldman M, Baud L. Mesangial cell-derived interleukin-10 modulates mesangial cell response to lipopolysaccharide. Am J Pathol 1995, 147:176-182. 1869879, 7604878.
120. Chadban SJ, Tesch GH, Foti R, Lan HY, Atkins RC, Nikolic-Paterson DJ. Interleukin-10 differentially modulates MHC class II expression by mesangial cells and macrophages in vitro and in vivo. Immunology 1998, 94:72-78. 1364333, 9708189.
121. Parry RG, Gillespie KM, Mathieson PW. Effects of type 2 cytokines on glomerular epithelial cells. Exp Nephrol 2001, 9:275-283. 10.1159/000052622, 11423727.
122. Kalechman Y, Sredni B, Weinstein T, Freidkin I, Tobar A, Albeck M, Gafter U. Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101. J Am Soc Nephrol 2003, 14:620-630. 10.1097/01.ASN.0000053415.29636.4F, 12595497.
123. Robertson TE, Nikolic-Paterson DJ, Hurst LA, Atkins RC, Chadban SJ. IL-10 induces mesangial cell proliferation via a PDGF-dependent mechanism. Clin Exp Immunol 2002, 130:241-244. 10.1046/j.1365-2249.2002.01975.x, 1906520, 12390311.
124. Chadban SJ, Tesch GH, Foti R, Atkins RC, Nikolic-Paterson DJ. Interleukin-10 is a mesangial cell growth factor in vitro and in vivo. Lab Invest 1997, 76:619-627.
125. Iglesias J, Marik PE, Levine JS. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 2003, 41:62-75. 10.1053/ajkd.2003.50024, 12500222.
126. Liu KD, Glidden DV, Eisner MD, Parsons PE, Ware LB, Wheeler A, Korpak A, Thompson BT, Chertow GM, Matthay MA. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Crit Care Med 2007, 35:2755-2761.
127. Choi DE, Jeong JY, Lim BJ, Na KR, Shin YT, Lee KW. Pretreatment with the tumor necrosis factor-a blocker etanercept attenuated ischemia-reperfusion renal injury. Transplant Proc 2009, 41:3590-3596. 10.1016/j.transproceed.2009.05.042, 19917350.
128. Duffield JS, Ware CF, Ryffel B, Savill J. Suppression by apoptotic cells defines tumor necrosis factor-mediated induction of glomerular mesangial cell apoptosis by activated macrophages. Am J Pathol 2001, 159:1397-1404. 10.1016/S0002-9440(10)62526-6, 1850510, 11583967.
129. Misaki T, Yamamoto T, Suzuki S, Fukasawa H, Togawa A, Ohashi N, Suzuki H, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Kitagawa M, Hishida A. Decrease in tumor necrosis factor-alpha receptor-associated death domain results from ubiquitin-dependent degradation in obstructive renal injury in rats. Am J Pathol 2009, 175:74-83. 10.2353/ajpath.2009.080884, 2708796, 19541932.
130. Meldrum KK, Misseri R, Metcalfe P, Dinarello CA, Hile KL, Meldrum DR. TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction. Am J Physiol Regul Integr Comp Physiol 2007, 292:R1456-R1464.
131. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003, 2:391-405. 10.1038/nrd1084, 12750742.
132. Brown Z, Strieter RM, Neild GH, Thompson RC, Kunkel SL, Westwick J. IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells. Kidney Int 1992, 42:95-101. 10.1038/ki.1992.266, 1386129.
133. Yokoo T, Kitamura M. Gene transfer of interleukin-1 receptor antagonist into the renal glomerulus via a mesangial cell vector. Biochem Biophys Res Commun 1996, 226:883-888. 10.1006/bbrc.1996.1444, 8831705.
134. Lan HY, Nikolic-Paterson DJ, Mu W, Vannice JL, Atkins RC. Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int 1995, 47:1303-1309. 10.1038/ki.1995.185, 7637259.
135. Nikolic-Paterson DJ, Lan HY, Hill PA, Vannice JL, Atkins RC. Suppression of experimental glomerulonephritis by the interleukin-1 receptor antagonist: inhibition of intercellular adhesion molecule-1 expression. J Am Soc Nephrol 1994, 4:1695-1700.
136. Tang WW, Feng L, Vannice JL, Wilson CB. Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. J Clin Invest 1994, 93:273-279. 10.1172/JCI116956, 293762, 7904269.
137. Lan HY, Nikolic-Paterson DJ, Zarama M, Vannice JL, Atkins RC. Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int 1993, 43:479-485. 10.1038/ki.1993.70, 8441245.
138. Rusai K, Huang H, Sayed N, Strobl M, Roos M, Schmaderer C, Heemann U, Lutz J. Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Transpl Int 2008, 21:572-580. 10.1111/j.1432-2277.2008.00651.x, 18363573.
139. Schmouder RL, Strieter RM, Wiggins RC, Chensue SW, Kunkel SL. In vitro and in vivo interleukin-8 production in human renal cortical epithelia. Kidney Int 1992, 41:191-198. 10.1038/ki.1992.26, 1593855.
140. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002, 168:6244-6252.
141. Kusner DJ, Luebbers EL, Nowinski RJ, Konieczkowski M, King CH, Sedor JR. Cytokine- and LPS-induced synthesis of interleukin-8 from human mesangial cells. Kidney Int 1991, 39:1240-1248. 10.1038/ki.1991.157, 1895676.
142. Brown Z, Strieter RM, Chensue SW, Ceska M, Lindley I, Neild GH, Kunkel SL, Westwick J. Cytokine-activated human mesangial cells generate the neutrophil chemoattractant, interleukin 8. Kidney Int 1991, 40:86-90. 10.1038/ki.1991.184, 1921160.
143. Liu KD, Altmann C, Smits G, Krawczeski CD, Edelstein CL, Devarajan P, Faubel S. Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care 2009, 13:R104. 10.1186/cc7940, 2750143, 19570208.
144. Liangos O, Kolyada A, Tighiouart H, Perianayagam MC, Wald R, Jaber BL. Interleukin-8 and acute kidney injury following cardiopulmonary bypass: a prospective cohort study. Nephron Clin Pract 2009, 113:c148-c154. 10.1159/000232595, 2821432, 19672112.
145. Tsai CY, Yu CL, Wu TH, Hsieh SC, Tsai YY. Proinflammatory cytokines enhance COX-1 gene expression in cultured rat glomerular mesangial cells. Int Immunopharmacol 2004, 4:47-56. 10.1016/j.intimp.2003.10.003, 14975359.
146. Garin EH, West L, Zheng W. Effect of interleukin-8 on glomerular sulfated compounds and albuminuria. Pediatr Nephrol 1997, 11:274-279. 10.1007/s004670050276, 9203172.
147. Driscoll KE. Macrophage inflammatory proteins: biology and role in pulmonary inflammation. Exp Lung Res 1994, 20:473-490. 10.3109/01902149409031733, 7882902.
148. Shastry S, James LR. Homocysteine-induced macrophage inflammatory protein-2 production by glomerular mesangial cells is mediated by PI3 kinase and p38 MAPK. J Inflamm (Lond) 2009, 6:27. 10.1186/1476-9255-6-27, 19781090.
149. Walpen S, Beck KF, Schaefer L, Raslik I, Eberhardt W, Schaefer RM, Pfeilschifter J. Nitric oxide induces MIP-2 transcription in rat renal mesangial cells and in a rat model of glomerulonephritis. FASEB J 2001, 15:571-573.
150. Fujita T, Yamabe H, Shimada M, Murakami R, Kumasaka R, Nakamura N, Osawa H, Okumura K. Thrombin enhances the production of monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 in cultured rat glomerular epithelial cells. Nephrol Dial Transplant 2008, 23:3412-3417. 10.1093/ndt/gfn352, 18622025.
151. Luo Y, Lloyd C, Gutierrez-Ramos JC, Dorf ME. Chemokine amplification in mesangial cells. J Immunol 1999, 163:3985-3992.
152. Feng L, Xia Y, Yoshimura T, Wilson CB. Modulation of neutrophil influx in glomerulonephritis in the rat with anti-macrophage inflammatory protein-2 (MIP-2) antibody. J Clin Invest 1995, 95:1009-1017. 10.1172/JCI117745, 441434, 7883948.
153. Roche JK, Keepers TR, Gross LK, Seaner RM, Obrig TG. CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation. Am J Pathol 2007, 170:526-537. 10.2353/ajpath.2007.060366, 1851848, 17255321.
154. Ueland JM, Gwira J, Liu ZX, Cantley LG. The chemokine KC regulates HGF-stimulated epithelial cell morphogenesis. Am J Physiol Renal Physiol 2004, 286:F581-F589. 10.1152/ajprenal.00289.2003, 14600031.
155. Viedt C, Dechend R, Fei J, Hansch GM, Kreuzer J, Orth SR. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. J Am Soc Nephrol 2002, 13:1534-1547. 10.1097/01.ASN.0000015609.31253.7F, 12039983.
156. Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, Hieshima K, Maruyama H, Miyazaki J, Yoshie O, Nose M, Fujita S. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003, 48:2555-2566. 10.1002/art.11231, 13130475.
157. Tesch GH, Schwarting A, Kinoshita K, Lan HY, Rollins BJ, Kelley VR. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest 1999, 103:73-80. 10.1172/JCI4876, 407867, 9884336.
158. Ninichuk V, Clauss S, Kulkarni O, Schmid H, Segerer S, Radomska E, Eulberg D, Buchner K, Selve N, Klussmann S, Anders HJ. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 2008, 172:628-637. 10.2353/ajpath.2008.070601, 2258250, 18258851.
159. Clauss S, Gross O, Kulkarni O, vila-Ferrufino A, Radomska E, Segerer S, Eulberg D, Klussmann S, Anders HJ. Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deffcient mice with autosomal recessive Alport nephropathy. J Pathol 2009, 218:40-47. 10.1002/path.2505, 19156777.
160. Wenzel U, Schneider A, Valente AJ, Abboud HE, Thaiss F, Helmchen UM, Stahl RA. Monocyte chemoattractant protein-1 mediates monocyte/macrophage influx in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int 1997, 51:770-776. 10.1038/ki.1997.108, 9067909.
161. Tang WW, Qi M, Warren JS. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int 1996, 50:665-671. 10.1038/ki.1996.363, 8840300.
162. Giunti S, Pinach S, Arnaldi L, Viberti G, Perin PC, Camussi G, Gruden G. The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells. Kidney Int 2006, 69:856-863. 10.1038/sj.ki.5000197, 16518346.
163. Burt D, Salvidio G, Tarabra E, Barutta F, Pinach S, Dentelli P, Camussi G, Perin PC, Gruden G. The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. Am J Pathol 2007, 171:1789-1799. 10.2353/ajpath.2007.070398, 2111103, 18055544.
164. Shimizu H, Maruyama S, Yuzawa Y, Kato T, Miki Y, Suzuki S, Sato W, Morita Y, Maruyama H, Egashira K, Matsuo S. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003, 14:1496-1505. 10.1097/01.ASN.0000069223.98703.8E, 12761250.
165. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, Gutierrez-Ramos JC. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997, 185:1371-1380. 10.1084/jem.185.7.1371, 2196251, 9104823.
166. Schneider A, Panzer U, Zahner G, Wenzel U, Wolf G, Thaiss F, Helmchen U, Stahl RA. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int 1999, 56:135-144. 10.1046/j.1523-1755.1999.00543.x, 10411686.
167. Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME, Cavallo-Perin P, Camussi G, Gruden G. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 2008, 51:198-207.
168. Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G, Gambino R, Vergola D, Pinach S, Perin PC, Camussi G, Gruden G. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009, 58:2109-2118. 10.2337/db08-0895, 2731530, 19587356.
169. Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, Holdsworth SR, Tipping PG. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003, 14:1487-1495. 10.1097/01.ASN.0000065550.13931.00, 12761249.
170. Seo JY, Park J, Yu MR, Kim YS, Ha H, Lee HB. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes. Am J Nephrol 2009, 30:481-490. 10.1159/000242477, 19786738.
171. Hertig A, Berrou J, Allory Y, Breton L, Commo F, Costa De Beauregard MA, Carmeliet P, Rondeau E. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J 2003, 17:1904-1906.
172. Matsuo S, Lopez-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 2005, 67:2221-2238. 10.1111/j.1523-1755.2005.00327.x, 15882265.
173. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005, 67:1297-1307. 10.1111/j.1523-1755.2005.00207.x, 15780082.
174. Hu K, Mars WM, Liu Y. Novel actions of tissue-type plasminogen activator in chronic kidney disease. Front Biosci 2008, 13:5174-5186. 2650246, 18508579.
175. Roelofs JJ, Rouschop KM, Leemans JC, Claessen N, de Boer AM, Frederiks WM, Lijnen HR, Weening JJ, Florquin S. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 2006, 17:131-140.
176. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002, 110:1525-1538. 151817, 12438450.
177. Haraguchi M, Border WA, Huang Y, Noble NA. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 2001, 59:2146-2155.
178. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997, 185:963-968. 10.1084/jem.185.5.963, 2196158, 9120402.
179. Gupta A, Williams MD, Macias WL, Molitoris BA, Grinnell BW. Activated protein C and acute kidney injury: Selective targeting of PAR-1. Curr Drug Targets 2009, 10:1212-1226. 10.2174/138945009789753291, 19715537.
180. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000, 95:3781-3787.
181. Park SW, Chen SW, Kim M, D'Agati VD, Lee HT. Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice. Kidney Int 2009, 76:739-750. 10.1038/ki.2009.255, 19625989.
182. Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S, Galbreath EJ, Swanson BA, Jones BE, Grinnell BW. Distinct functions of activated protein C differentially attenuate acute kidney injury. J Am Soc Nephrol 2009, 20:267-277. 10.1681/ASN.2008030294, 2637057, 19092124.
183. Gupta A, Berg DT, Gerlitz B, Sharma GR, Syed S, Richardson MA, Sandusky G, Heuer JG, Galbreath EJ, Grinnell BW. Role of protein C in renal dysfunction after polymicrobial sepsis. J Am Soc Nephrol 2007, 18:860-867. 10.1681/ASN.2006101167, 17301189.
184. Gupta A, Rhodes GJ, Berg DT, Gerlitz B, Molitoris BA, Grinnell BW. Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol 2007, 293:F245-F254. 10.1152/ajprenal.00477.2006, 17409278.
185. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007, 13:1349-1358. 10.1038/nm1667, 17982464.
186. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF--a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007, 106:32-37. 10.1159/000101798, 17570946.
187. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004, 65:2003-2017. 10.1111/j.1523-1755.2004.00621.x, 15149314.
188. Shimizu A, Masuda Y, Mori T, Kitamura H, Ishizaki M, Sugisaki Y, Fukuda Y. Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 2004, 15:2655-2665. 10.1097/01.ASN.0000141038.28733.F2, 15466270.
189. Suga S, Kim YG, Joly A, Puchacz E, Kang DH, Jefferson JA, Abraham JA, Hughes J, Johnson RJ, Schreiner GF. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int 2001, 60:1297-1308. 10.1046/j.1523-1755.2001.00935.x, 11576344.
190. Muller-Deile J, Worthmann K, Saleem M, Tossidou I, Haller H, Schiffer M. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 2009, 297:F1656-F1667. 10.1152/ajprenal.00275.2009, 19828679.
191. Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger DD, Janjic N, Floege J. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999, 104:913-923. 10.1172/JCI6740, 408553, 10510332.
192. Kanellis J, Fraser S, Katerelos M, Power DA. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am J Physiol Renal Physiol 2000, 278:F905-F915.
193. Feliers D, Chen X, Akis N, Choudhury GG, Madaio M, Kasinath BS. VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Kidney Int 2005, 68:1648-1659. 10.1111/j.1523-1755.2005.00575.x, 16164642.
194. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model; II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001, 12:1448-1457.
195. Satchell SC, Anderson KL, Mathieson PW. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 2004, 15:566-574. 10.1097/01.ASN.0000115397.22519.03, 14978158.
196. Chen J, Braet F, Brodsky S, Weinstein T, Romanov V, Noiri E, Goligorsky MS. VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. Am J Physiol Cell Physiol 2002, 282:C1053-C1063.
197. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998, 187:1205-1213. 10.1084/jem.187.8.1205, 2212219, 9547332.
198. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997, 186:2045-2050. 10.1084/jem.186.12.2045, 2199173, 9396774.
199. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ-system failure. Ann Surg 1985, 202:685-693. 10.1097/00000658-198512000-00004, 1250999, 4073980.
200. Gurkan OU, O'Donnell C, Brower R, Ruckdeschel E, Becker PM. Differential effects of mechanical ventilatory strategy on lung injury and systemic organ inflammation in mice. Am J Physiol Lung Cell Mol Physiol 2003, 285:L710-L718.
201. Hegeman MA, Hennus MP, Heijnen CJ, Specht PA, Lachmann B, Jansen NJ, van Vught AJ, Cobelens PM. Ventilator-induced endothelial activation and inflammation in the lung and distal organs. Crit Care 2009, 13:R182. 10.1186/cc8168, 2811914, 19917112.
202. Chiumello D, Pristine G, Slutsky AS. Mechanical ventilation affects local and systemic cytokines in an animal model of acute respiratory distress syndrome. Am J Respir Crit Care Med 1999, 160:109-116.
203. Guery BP, Welsh DA, Viget NB, Robriquet L, Fialdes P, Mason CM, Beaucaire G, Bagby GJ, Neviere R. Ventilation-induced lung injury is associated with an increase in gut permeability. Shock 2003, 19:559-563. 10.1097/01.shk.0000070738.34700.bf, 12785012.
204. Haitsma JJ, Uhlig S, Goggel R, Verbrugge SJ, Lachmann U, Lachmann B. Ventilator-induced lung injury leads to loss of alveolar and systemic compartmentalization of tumor necrosis factor-alpha. Intensive Care Med 2000, 26:1515-1522. 10.1007/s001340000648, 11126266.
205. Haitsma JJ, Uhlig S, Lachmann U, Verbrugge SJ, Poelma DL, Lachmann B. Exogenous surfactant reduces ventilator-induced decompartmentalization of tumor necrosis factor alpha in absence of positive end-expiratory pressure. Intensive Care Med 2002, 28:1131-1137. 10.1007/s00134-002-1377-4, 12185437.
206. Haitsma JJ, Uhlig S, Verbrugge SJ, Goggel R, Poelma DL, Lachmann B. Injurious ventilation strategies cause systemic release of IL-6 and MIP-2 in rats in vivo. Clin Physiol Funct Imaging 2003, 23:349-353. 10.1046/j.1475-0961.2003.00518.x, 14617266.
207. Herrera MT, Toledo C, Valladares F, Muros M, Diaz-Flores L, Flores C, Villar J. Positive end-expiratory pressure modulates local and systemic inflammatory responses in a sepsis-induced lung injury model. Intensive Care Med 2003, 29:1345-1353. 10.1007/s00134-003-1756-5, 12698249.
208. Murphy DB, Cregg N, Tremblay L, Engelberts D, Laffey JG, Slutsky AS, Romaschin A, Kavanagh BP. Adverse ventilatory strategy causes pulmonary-to-systemic translocation of endotoxin. Am J Respir Crit Care Med 2000, 162:27-33.
209. Oliveira-Junior IS, Pinheiro BV, Silva ID, Salomao R, Zollner RL, Beppu OS. Pentoxifylline decreases tumor necrosis factor and interleukin-1 during high tidal volume. Braz J Med Biol Res 2003, 36:1349-1357. 10.1590/S0100-879X2003001000011, 14502367.
210. Schortgen F, Bouadma L, Joly-Guillou ML, Ricard JD, Dreyfuss D, Saumon G. Infectious and inflammatory dissemination are affected by ventilation strategy in rats with unilateral pneumonia. Intensive Care Med 2004, 30:693-701. 10.1007/s00134-003-2147-7, 14740157.
211. Vreugdenhil HA, Heijnen CJ, Plotz FB, Zijlstra J, Jansen NJ, Haitsma JJ, Lachmann B, van Vught AJ. Mechanical ventilation of healthy rats suppresses peripheral immune function. Eur Respir J 2004, 23:122-128. 10.1183/09031936.03.00035003, 14738243.
212. Wolthuis EK, Vlaar AP, Choi G, Roelofs JJ, Juffermans NP, Schultz MJ. Mechanical ventilation using non-injurious ventilation settings causes lung injury in the absence of pre-existing lung injury in healthy mice. Crit Care 2009, 13:R1-R11. 10.1186/cc7688, 2688111, 19152704.
213. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001, 159:599-608. 10.1016/S0002-9440(10)61731-2, 1850560, 11485918.
214. Hakroush S, Moeller MJ, Theilig F, Kaissling B, Sijmonsma TP, Jugold M, Akeson AL, Traykova-Brauch M, Hosser H, Hähnel B, Gröne HJ, Koesters R, Kriz W. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am J Pathol 2009, 175:1883-1895. 10.2353/ajpath.2009.080792, 2774053, 19834063.
215. Leonard EC, Friedrich JL, Basile DP. VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol Renal Physiol 2008, 295:F1648-F1657. 10.1152/ajprenal.00099.2008, 2604827, 18799550.
216. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001, 12:993-1000.
217. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, Johnson RJ. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000, 58:2390-2399. 10.1046/j.1523-1755.2000.00422.x, 11115072.
218. Li ZD, Bork JP, Krueger B, Patsenker E, Schulze-Krebs A, Hahn EG, Schuppan D. VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 2005, 334:1049-1060. 10.1016/j.bbrc.2005.07.005, 16039615.
219. Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, Shen W, Kopp JB, Thomas DB, Tufro A. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 2010, 77:989-999. 10.1038/ki.2010.64, 20375978.
220. Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, Nagata M, Watanabe T, Fan J. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007, 18:2094-2104. 10.1681/ASN.2006010075, 17554151.
221. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, Shimizu F, Shibuya M, Matsushima K, Yokoyama H, Egashira K, Kaneko S. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 2006, 69:1986-1995. 10.1038/sj.ki.5000439, 16641924.